Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
The TRANSCEND study is looking into whether a single 25mg dose of psilocybin, a chemical found in 'magic mushrooms,' can help adults aged 18 to 65 who are experiencing both long-term nerve pain and depression that hasn't responded to usual treatments. Previous studies have shown psilocybin might have lasting antidepressant effects when combined with talking therapy. This research aims to understand if this treatment is practical, safe, and potentially effective for this specific group of patients. It focuses on people whose pain is due to nerve damage and whose depression has been difficult to treat, even after trying different medications. The study will assess if this approach can improve their symptoms, with a strong emphasis on patient safety and well-being.
At a glance
What is this study about?
This research study, called TRANSCEND, is investigating a new way to help people who are living with two challenging conditions: long-term nerve pain (neuropathic pain) and depression that hasn't improved with standard treatments. Nerve pain can be very difficult to manage, and when combined with depression that doesn't go away, it can significantly affect a person's quality of life.
The study is using a substance called psilocybin. You might know psilocybin as the active ingredient in 'magic mushrooms.' In this study, it's given as a carefully measured single dose. We're interested in whether this treatment, which has shown promise in helping with depression in other studies, might also be helpful for individuals who are struggling with both ongoing nerve pain and hard-to-treat depression. The main goals are to find out if this treatment is generally safe, if people can tolerate it well, and if it shows any early signs of reducing symptoms for those involved.
It's important to remember that this is a research study. This means we're still learning about how psilocybin works for these specific conditions. The researchers want to gather more information to see if this could be a promising new approach for patients who haven't found relief with current options.
Key takeaways
- It's for people with both long-term nerve pain and hard-to-treat depression.
- The study uses a single dose of psilocybin.
- Researchers want to see if it's safe and helps symptoms.
- This is a research study, not a standard treatment yet.
- Close medical supervision is provided.
Who may be eligible?
This study is looking for adults between 18 and 65 years old who are currently seeking help as outpatients. You must be able to understand the study information and be willing to follow all the study steps.
To join, you would need to have been diagnosed with depression that hasn't improved after trying at least two different antidepressant medications. You would also need a diagnosis of long-lasting nerve pain that is moderate to severe and hasn't significantly improved with at least two standard pain medications.
There are also some health checks to make sure the treatment is safe for you, including having healthy kidney function. For women who could become pregnant, specific contraception requirements will apply.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 18 and 65 years old?
- Do you have chronic nerve pain that is moderate to severe?
- Have you tried at least two different pain medications without much relief?
- Do you have depression that hasn't significantly improved after trying at least two different antidepressants?
- Are you able to speak and understand English well enough for consent and questionnaires?
What does participation involve?
If you join the study, you'll first have screening visits to see if the study is right for you. This will include detailed interviews about your depression and pain, and some physical checks and blood tests. If you're eligible, you would receive a single dose of 25mg of psilocybin under careful medical supervision.
Throughout the study, you would have regular appointments to track your progress and any changes in your symptoms. These appointments might involve answering questionnaires about your pain and mood. The researchers will be looking closely at how you feel and how your body reacts to the treatment. The total duration of your involvement in the study will be explained in detail if you are considered for participation.
Potential risks and benefits
Locations (1)
- Centre for Addiction and Mental HealthVerified postcodeToronto, Canada· Recruiting
Common questions
What is psilocybin?
Psilocybin is a natural compound found in certain types of mushrooms, sometimes called 'magic mushrooms.' In this study, it's used as a specific dose to see if it can help with depression and pain.
Is this a new treatment?
While psilocybin has been known for a long time, its use in a controlled medical setting for conditions like depression and chronic pain is still being researched, and it's not a standard treatment yet.
Will I be monitored closely?
Yes, if you participate, you will be very closely monitored by medical staff throughout the treatment session and during follow-up appointments to ensure your safety and well-being.
What kind of pain is this study for?
This study is specifically for chronic neuropathic pain, which is pain caused by damage to nerves, rather than other types of long-term pain.
What does 'treatment-resistant depression' mean?
It means your depression hasn't gotten better, or hasn't improved enough, after trying at least two different types of antidepressant medications at adequate doses and for a long enough time.
How to find out more
Muhammad Ishrat Husain, MBBS, MD
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.